Response to "the corporate coauthor".
作者信息
Wager Elizabeth, Jacobs Adam
出版信息
J Gen Intern Med. 2005 Jul;20(7):672. doi: 10.1111/j.1525-1497.2005.051181.x.
Abstract
摘要
相似文献
1
Response to "the corporate coauthor".
J Gen Intern Med. 2005 Jul;20(7):672. doi: 10.1111/j.1525-1497.2005.051181.x.
2
The corporate coauthor.
J Gen Intern Med. 2005 Jun;20(6):546-8. doi: 10.1111/j.1525-1497.2005.05857.x.
3
[Knowledge on feet of clay].
Lakartidningen. 2008;105(19):1405-6.
4
[Ghostwriting].
Tidsskr Nor Laegeforen. 2008 May 1;128(9):1039.
5
[The journals must honestly tell who is doing the job].
Lakartidningen. 2008;105(19):1406-7.
6
Scientific discourse, corporate ghostwriting, journal policy, and public trust.
J Gen Intern Med. 2005 Jun;20(6):550-1. doi: 10.1111/j.1525-1497.2005.41008.x.
7
The sins of ghostwriting.
Am J Ther. 2008 Jul-Aug;15(4):297-8. doi: 10.1097/MJT.0b013e318180f387.
8
Sponsorship, authorship and accountability.
CMAJ. 2001 Sep 18;165(6):786-8.
9
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Mayo Clin Proc. 2010 Feb;85(2):196-7; author 201-4. doi: 10.4065/mcp.2009.0616.
10
Comments on "The corporate author".
J Gen Intern Med. 2005 Oct;20(10):972; author reply 972-3. doi: 10.1111/j.1525-1497.2005.051391_1.x.
引用本文的文献
1
A literature review of non-financial conflicts of interest in healthcare research and publication.
BMC Med Ethics. 2025 May 15;26(1):61. doi: 10.1186/s12910-025-01221-5.
本文引用的文献
1
The corporate coauthor.
J Gen Intern Med. 2005 Jun;20(6):546-8. doi: 10.1111/j.1525-1497.2005.05857.x.
2
European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications.
Curr Med Res Opin. 2005 Feb;21(2):317-22. doi: 10.1185/030079905X25578.
3
Good publication practice for pharmaceutical companies.
Curr Med Res Opin. 2003;19(3):149-54. doi: 10.1185/030079903125001767.
4
When authorship fails. A proposal to make contributors accountable.
JAMA. 1997 Aug 20;278(7):579-85. doi: 10.1001/jama.278.7.579.
Zotero 插件